Holdings in Company

17 November 2011

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                              Holdings in Company                              

The Company announces that it has received notification that Helium Special
Situations Fund Limited has increased its beneficial interest in Scancell
Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents
approximately 9.06 per cent of the issued capital of the Company.

For further information contact:

Scancell Holdings Plc                                   + 44 (0)207 245 1100 
Professor Lindy Durrant/Dr Richard Goodfellow                                
                                                                             
Hansard Communications- Financial PR                    + 44 (0)207 245 1100 
Adam Reynolds/Guy McDougall                                                  
                                                                             
Zeus Capital - Nominated Adviser                        + 44 (0)161 831 1512 
Ross Andrews/Tom Rowley                                                      
                                                                             
XCAP Securities Plc - Broker                            [phone] 
Jon Belliss/ Adrian Kirk                                                     

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.